YenChen Huang

Head of Investment / Vice President
​Diamond Biofund

​​​​
​

YenChen Huang is currently Vice President of Diamond Biofund, the pioneering venture firm specializing in the healthcare sector and notably the first venture capital company listed on the Taiwan Stock Exchange. With a wealth of experience spanning close to two decades in the biotechnology industry, YenChen oversees investment operations with precision and insight. His expertise traverses various domains including biotech, medtech, medical services, and agricultural biotechnology. Diamond Biofund's investment portfolio, under his guidance, is strategically diversified across Taiwan, the United States, Israel, and mainland China.
Before his tenure in venture capital, Huang served as a manager at the Industrial Technology Research Institute (ITRI), where he played a pivotal role in spearheading R&D projects, conducting industry research, performing market analyses, and offering consulting services. His specialization in the biotech and medtech sectors laid the foundation for his subsequent success in the field of venture capital
YenChen has served as a director or supervisor for multiple biotech companies, assisting invested enterprises from the early stages of startup development to entering the capital market or being acquired, such as Sinew Pharma (6634:TT), 3D Global Biotech (6808:TT), Enimmune (6564:TT), S&S Healthcare Holding (4198:TT) , IOPtima (acquired by Chengdu Kanghong Pharmaceutical(002773:CH)), Iridium  Medical Technology, Tetanti Agribiotech, ImmunAdd Inc, Israeli-based EyeYon Medical, US-based Bilayer Therapeutics, and US-based Stemcyte. He received a Biophotonics Engineering MS degree from National Yang-Ming University and has completed a Supply Chain Management master's program at the Massachusetts Institute of Technology (MIT).

Speech title & Synopsis

​
Panel Discussion- Innovative Investment Strategies for New Drug Development
 

Panelist